Digital pathology firm Corista files to raise $10M
What's the deal? Corista has filed a notice with the US Securities and Exchange Commission (SEC) to raise up to $10,080,000 in new funding. The filing, made under Regulation D, discloses an equity offering with a date of first sale of 17 June 2026.
What's the endgame? Corista builds digital tools for pathology, spanning workflow, analytics, and collaboration. Its platform integrates whole-slide image scanning, image analytics, and laboratory and health record systems (LIS/EHRs) in a single environment.
The company pitches this as "Integrated Pathology," letting physicians collaborate, teach, and report while specialists handle remote digital consults. Researchers can also apply their own algorithms on its R&D platform.
Why now? Regulation D filings are made within 15 days of a first sale, so the raise is already underway rather than newly launched. The notice does not name investors or disclose a valuation.
The signal: Capital continues to flow toward the digitisation of diagnostics, where pathology remains a slower-moving corner of healthcare than radiology. Corista's raise is a modest bet on interoperability — connecting scanners, analytics, and records systems that have long operated apart.
Read more: SEC EDGAR · Intelligence360
